Register at: www.TorontoOttawaHeartSummit.com

PROGRAM DIRECTORS
Peter Liu, MD
Chief Scientific Officer
University of Ottawa Heart Institute
Michael Farkouh, MD
Peter Munk Chair in Multinational Trials
Director, Heart and Stroke Richard Lewar Centre of Excellence
________________________________________
PROGRAM AGENDA (http://torontoottawaheartsummit.com/agenda.html)

SYMPOSIUM OBJECTIVES

The overall goal of this joint symposium is to promote the exchange of existing knowledge from innovative cellular research, through translation, to foster dissemination and collaboration, leading to better cardiovascular outcomes.
At the end of this symposium, participants should be able to:
recognize moving targets in risk factor management and implement preventative cardiology recommendations and advocate health promotion
identify how machine learning and artificial intelligence can augment physician’s diagnostic skills and help tailor treatment to individual patient and disease
explain relevant screening and/or management strategies appropriate for CV risk stratification and prevention in at-risk populations
discuss new and emerging theories and management in heart failure, and differentiate between reduced and preserved ejection fraction patients
review appropriate management of anticoagulant and antiplatelet therapies across various cardiovascular conditions
summarize pharmacological and non-pharmacological options in atrial fibrillation management
consider emerging origins of atherosclerotic etiology and explore intervention targets
identify causative risk factors and treat according to guidelines to reduce burden of CV disease
evaluate effectiveness and potential limitations of current and emerging pharmacotherapy options for LDL reduction
review the latest guidelines and surrogate marker targets for management of diabetic heart disease
discuss evidence from late-breaking trial results and the impact on cardiovascular care
Why attend this symposium?
This year, our conference is joined with the International Symposium on Atherosclerosis (http://www.isa2018.org/). The joint program brings together the most exciting advances in cardiovascular disease and related cardiometabolic and cardiorenal medicine, from treatment to prevention and innovation to application. The program is unique because of its translational theme. The global faculty and participating audience represent the faces of cardiovascular medicine with a truly international perspective.
Who should attend?
Cardiologists, Internists & Primary Care Physicians; Cardiovascular Surgeons; Pediatric Cardiologist, Allied Health Professionals (ACNP, Nurses, Pharmacists); Heart Failure Care Teams; Trainees; Clinical Researchers; Research Scientists.

ACKNOWLEDGEMENT
Appreciation is expressed to the following in support of this program:
Platinum Sponsor:
Patrons:
Supporters:

________________________________________
CONTACT INFORMATION:
Shanas Mohamed, RN, BScN, CMP
Toronto General Hospital (UHN)
200 Elizabeth Street, 12 Eaton RM 325A,
Toronto, ON, M5G 2C4
Telephone +1 416-340-3721
E-mail shanas.mohamed@uhn.ca
Allison Conley
University of Ottawa Heart Institute
40 Ruskin Street,
Ottawa, ON, K1Y 4W7
E-mail aconley@ottawaheart.ca

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

Log in with your credentials

Forgot your details?